Cognition Therapeutics (CGTX) vs Equillium (EQ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Equillium (EQ) has outperformed Cognition Therapeutics (CGTX) over the past year, losing 2.0% versus a loss of 49.1%. Over five years, EQ leads with a -75.6% price change compared with -92.5% for CGTX. Equillium is the larger company by market cap ($90.0 million vs $83.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGTX | EQ |
|---|---|---|
| Share price | $0.8768 | $1.42 |
| Market cap | $83.38M | $90.04M |
| 1-day change | -2.06% | -1.39% |
| YTD return | -33.69% | -7.10% |
| 1-year return | -49.14% | -2.04% |
| 5-year return | -92.48% | -75.63% |
| EPS (TTM) | $-0.17 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.05 | $3.54 |
| 52-week low | $0.55 | $0.76 |
| Distance from 52-week high | -57.23% | -59.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +279.79% | +502.82% |
| Average volume | 534.62K | 583.72K |
| Shares outstanding | 95.09M | 63.41M |
| Employees | 14 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EQ has outperformed CGTX by 47.1 percentage points over the past year.
About Cognition Therapeutics
CGTX stock →Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
CGTX vs EQ FAQ
Which is bigger, Cognition Therapeutics or Equillium?
Equillium (EQ) is larger, with a market capitalization of $90.04M compared with $83.38M for Cognition Therapeutics (CGTX).
Which stock has performed better over the past year, CGTX or EQ?
EQ returned -2.04% over the past 12 months, compared with -49.14% for CGTX (price return, excluding dividends). Past performance does not predict future results.
Are Cognition Therapeutics and Equillium in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cognition Therapeutics and Biotechnology: Pharmaceutical Preparations for Equillium.